Printer Friendly

Quick-Med Technologies, Inc. Retains Elman Technology Law, P.C.

GAINESVILLE, Fla. -- Quick-Med Technologies, Inc. (OTCBB: QMDT) (the "Company") is pleased to announce that the Company has retained the services of Elman Technology Law, P.C. ("Elman") to handle all patent, trademark, and copyright matters. Elman has extensive experience in practice areas that are central to the Company's intellectual property portfolio. Mr. Gerry Elman is also the founder and editor-in-chief of Biotechnology Law Report, published by Mary Ann Liebert, Inc.

"We are delighted to be entrusted with helping the company manage and enhance its intellectual property. This includes patents in the United States and foreign jurisdictions, some of which are jointly owned with the University of Florida Research Foundation," said patent attorney Gerry J. Elman.

Incorporated in 1988, Elman Technology Law, P.C. has extensive experience in patent, trademark and other aspects of the law related to technology, enabling the firm to provide clients, in a close working relationship, with the educated guidance needed to develop an innovation from concept stage through realization in the marketplace. Elman Technology Law is a member of the Eastern Technology Council and a charter partner of International Business Law Services.

Recently Issued Quick-Med Technologies Patents

In addition, Quick-Med Technologies also announced the issuance by the Australian patent office of a patent entitled "Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication", for NIMBUS(TM) antimicrobial technology, as well as a corresponding patent issued by the Eurasian patent office and registered with the Russian Federation.


Novel Intrinsically Micro Biocidal Utility Substrate, otherwise known as NIMBUS(TM), refers to a family of patents, techniques, and other intellectual property in which advanced polymer chemistry is used to bond biologically active molecules onto substrates. Choices of the substrate, the bonded molecules, or the method of bonding creates products that can be modified to produce varying product attributes. The most significant commercial application of NIMBUS(TM) is in creating antimicrobial products. By altering aspects of the formulation, the product can be made to be super-absorbent as well as antimicrobial. Alternatively, the product can be made to have hemostatic properties, or the ability to stop bleeding. A distinguishing feature of NIMBUS(TM) treated material, as demonstrated in a range of standardized tests by us and a third party microbiology testing company, is that the microbicide is effective against a broad range of bacteria and fungi, and the active ingredient does not leach off the substrate.

About Quick-Med Technologies, Inc.

Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company's two core products under development are: (1) MultiStat(TM), a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS(TM), a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies' website: or email: for further information.

Certain statements in this press release constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, certainties and other factors, which may cause the actual results, performance of achievements of Quick-Med Technologies, Inc. (the "Company") to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The approval of the "Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication" patent for the NIMBUS(TM) technology by the Australian and Eurasian patent office should not be construed as an indication in any way whatsoever of having any positive impact upon our future financial performance. The Company's future operating results are dependent upon many factors, including whether the Company will ever successfully launch its potential technologies and/or products and the risk factors contained in its periodic and other filings, which are available for review at Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 13, 2005
Previous Article:Keenan Provides ConsumerAdvance to Vista USD for January 2005 Enrollment; First School District to Elect New Consumer-Directed Health Benefit...
Next Article:Harmonic Announces Preliminary Fourth Quarter Net Sales; Results Exceed Revenue Guidance.

Related Articles
City/Region Digest.
Autopsy suggests sex assault.
Teen faces murder charge.
Boy, 14, formally charged in murder.
New Jersey Exit 8A submarket growing.
Buyers' guide to thermoplastics.
Back to the future for 1359 B'way.
Forest City Ratner Companies.
Two new long-term leases take distribution center to 100%.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters